Related Experiment Video
Updated: Jul 9, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with
Katsuomi Iwakura1, Hiroshi Ito, Shigeo Kawano
1Division of Cardiology, Sakurabashi Watanabe Hospital, 2-4-32, Umeda, Kita-ku, Osaka 5300001, Japan.
European Heart Journal
|January 13, 2006
Summary
Statin pre-treatment before myocardial infarction reduces the no-reflow phenomenon and improves heart function. This effect is independent of cholesterol levels, suggesting a direct benefit on microvascular integrity.
Area of Science:
- Cardiology
- Cardiovascular Research
- Pharmacology
Background:
- Early statin therapy improves outcomes post-acute coronary syndrome.
- The no-reflow phenomenon is a key determinant of prognosis after acute myocardial infarction.
Purpose of the Study:
- To investigate the impact of pre-admission statin treatment on the development of no-reflow after acute myocardial infarction.
- To assess the effect of statin pre-treatment on left ventricular function and dimensions post-myocardial infarction.
Main Methods:
- Intracoronary myocardial contrast echocardiography in 293 acute myocardial infarction patients.
- Comparison of no-reflow incidence between patients with and without pre-admission statin treatment.
- Multivariable logistic regression analysis to identify predictors of no-reflow.
Main Results:
- No significant difference in no-reflow incidence based on hypercholesterolemia.
- Significantly lower no-reflow incidence (9.1% vs. 34.6%) in patients on chronic statin pre-treatment (P=0.003).
- Statin pre-treatment predicted better long-term wall motion, smaller left ventricular dimensions, and improved ejection fraction.
Conclusions:
- Chronic statin pre-treatment preserves microvascular integrity post-myocardial infarction.
- The beneficial effect of statins is independent of lipid-lowering effects.
- Pre-treatment with statins leads to better functional recovery after acute myocardial infarction.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...